We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now.
TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by BITG. The company is described as a clinical-stage biopharmaceutical firm targeting diseases associated with human aging through analysis of large human datasets to identify biological markers that influence long-term health outcomes. The outlook highlights a roughly four-year cash runway and upcoming clinical catalysts, including BGE-102 expected in the second half of 2026 and BGE-105 anticipated in mid-2027. The lead cardiovascular risk program is viewed as biologically de-risked based on evidence linking reductions in systemic inflammation with improved clinical outcomes, supporting the firm’s positive stance on the development pipeline.
Additionally, on May 8, BioAge Labs, Inc. (NASDAQ:BIOA) reported first-quarter 2026 financial results for the period ended March 31, 2026, alongside a business update. Collaboration revenue increased to $2.8 million from $1.5 million a year earlier, driven by higher activity under its Novartis agreement.
Research and development expenses rose to $20.4 million, reflecting increased spending on the BGE-102 program, including late-stage Phase 1 completion work, preparation for upcoming Phase 2 cardiovascular risk studies, and expansion into additional proof-of-concept trials. Additional R&D costs were driven by other pipeline programs and manufacturing efforts. General and administrative expenses increased to $7.7 million due to higher personnel costs and legal expenses. Net loss widened to $22.3 million, while cash reserves stood at approximately $384.9 million, supporting operations through 2029.
BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company developing therapies for metabolic and age-related diseases by targeting the biological drivers of aging.
While we acknowledge the risk and potential of BIOA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BIOA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
